Literature DB >> 2143883

Macrophage histology in paraffin-embedded multiple sclerosis plaques is demonstrated by the monoclonal pan-macrophage marker HAM-56: correlation with chronicity of the lesion.

C W Adams1, R N Poston.   

Abstract

Using the monoclonal antibody HAM-56 with the avidin-biotin method on recent or archival paraffin-embedded tissue from multiple sclerosis brains, we have been able to distinguish between acute, chronic active and inactive lesions. HAM-56 stains all macrophages, monocytes and at least some microglia; it is the only pan-macrophage marker to our knowledge that can be satisfactorily used on conventional paraffin sections. A much narrower range of mainly perivascular macrophages in acute plaques of multiple sclerosis is stained with MAC-387, anti-muramidase and anti-alpha1-anti-trypsin. The acute plaques show HAM-56-stained macrophages throughout the lesion, and these macrophages exhibit profiles of phospholipid-rich myelinic bodies, which are also usually stainable with Luxol fast blue. Active ongoing lesions show a rim of macrophages at the edge of the lesion. These macrophages show profiles of large vacuoles, thought to represent the sudanophilic esterified cholesterol formed during demyelination. Inactive cases show none of these features; the few perivascular macrophages present often contain the end product of lipid peroxidation, ceroidlipofuscin.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2143883     DOI: 10.1007/bf00308926

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  15 in total

1.  The onset and progression of the lesion in multiple sclerosis.

Authors:  C W Adams
Journal:  J Neurol Sci       Date:  1975-06       Impact factor: 3.181

2.  Blood-brain barrier damage in acute multiple sclerosis plaques. An immunocytological study.

Authors:  D Gay; M Esiri
Journal:  Brain       Date:  1991-02       Impact factor: 13.501

3.  Pathology, histochemistry and immunocytochemistry of lesions in acute multiple sclerosis.

Authors:  C W Adams; R N Poston; S J Buk
Journal:  J Neurol Sci       Date:  1989-09       Impact factor: 3.181

4.  The relation between enzyme activity and neuroglia in early plaques of multiple sclerosis.

Authors:  M Z Ibrahim; C W Adams
Journal:  J Pathol Bacteriol       Date:  1965-07

5.  On the immunopathology of plaque development and repair in multiple sclerosis.

Authors:  C S Raine; L C Scheinberg
Journal:  J Neuroimmunol       Date:  1988-12       Impact factor: 3.478

Review 6.  Pathology of multiple sclerosis: progression of the lesion.

Authors:  C W Adams
Journal:  Br Med Bull       Date:  1977-01       Impact factor: 4.291

7.  The significance of perivascular infiltrations in multiple sclerosis.

Authors:  A Guseo; K Jellinger
Journal:  J Neurol       Date:  1975-12-02       Impact factor: 4.849

8.  Remyelination in multiple sclerosis.

Authors:  J W Prineas; F Connell
Journal:  Ann Neurol       Date:  1979-01       Impact factor: 10.422

9.  Human atherosclerosis. II. Immunocytochemical analysis of the cellular composition of human atherosclerotic lesions.

Authors:  A M Gown; T Tsukada; R Ross
Journal:  Am J Pathol       Date:  1986-10       Impact factor: 4.307

10.  Inflammatory vasculitis in multiple sclerosis.

Authors:  C W Adams; R N Poston; S J Buk; Y S Sidhu; H Vipond
Journal:  J Neurol Sci       Date:  1985-07       Impact factor: 3.181

View more
  9 in total

1.  Recently infiltrating MAC387(+) monocytes/macrophages a third macrophage population involved in SIV and HIV encephalitic lesion formation.

Authors:  Caroline Soulas; Cecily Conerly; Woong-Ki Kim; Tricia H Burdo; Xavier Alvarez; Andrew A Lackner; Kenneth C Williams
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

2.  Tissue-resident macrophages are productively infected ex vivo by primary X4 isolates of human immunodeficiency virus type 1.

Authors:  Prerana Jayakumar; Irina Berger; Frank Autschbach; Mark Weinstein; Benjamin Funke; Eric Verdin; Mark A Goldsmith; Oliver T Keppler
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

3.  The expression of fetuin in the development and maturation of the hemopoietic and immune systems.

Authors:  K Dziegielewska; W M Brown; A Deal; K A Foster; E J Fry; N R Saunders
Journal:  Histochem Cell Biol       Date:  1996-09       Impact factor: 4.304

4.  Association of low numbers of CD206-positive cells with loss of ICC in the gastric body of patients with diabetic gastroparesis.

Authors:  C E Bernard; S J Gibbons; I S Mann; L Froschauer; H P Parkman; S Harbison; T L Abell; W J Snape; W L Hasler; R W McCallum; I Sarosiek; L A B Nguyen; K L Koch; J Tonascia; F A Hamilton; M L Kendrick; K R Shen; P J Pasricha; G Farrugia
Journal:  Neurogastroenterol Motil       Date:  2014-07-13       Impact factor: 3.598

5.  SIV encephalitis lesions are composed of CD163(+) macrophages present in the central nervous system during early SIV infection and SIV-positive macrophages recruited terminally with AIDS.

Authors:  Brian T Nowlin; Tricia H Burdo; Cecily C Midkiff; Marco Salemi; Xavier Alvarez; Kenneth C Williams
Journal:  Am J Pathol       Date:  2015-05-08       Impact factor: 4.307

6.  LAG3 expression in active Mycobacterium tuberculosis infections.

Authors:  Bonnie L Phillips; Smriti Mehra; Muhammad H Ahsan; Moises Selman; Shabaana A Khader; Deepak Kaushal
Journal:  Am J Pathol       Date:  2014-12-27       Impact factor: 4.307

7.  Evidence for multiple pathologic and protective mechanisms of murine cerebral malaria.

Authors:  V M Jennings; A A Lal; R L Hunter
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

8.  Inducible nitric oxide synthase and nitrotyrosine are found in monocytes/macrophages and/or astrocytes in acute, but not in chronic, multiple sclerosis.

Authors:  E L Oleszak; E Zaczynska; M Bhattacharjee; C Butunoi; A Legido; C D Katsetos
Journal:  Clin Diagn Lab Immunol       Date:  1998-07

Review 9.  Albumin and multiple sclerosis.

Authors:  Steven M LeVine
Journal:  BMC Neurol       Date:  2016-04-12       Impact factor: 2.474

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.